期刊
PHARMACEUTICALS
卷 14, 期 11, 页码 -出版社
MDPI
DOI: 10.3390/ph14111171
关键词
CRISPR; gene editing; infectious diseases; antimicrobial resistance; parasitology
资金
- FCT/MCTES [UIDB/50011/2020, UIDP/50011/2020]
The development of gene editing tools such as ZFNs, TALENs, Cas9, and HEs has led to significant advancements in the field of science, especially with the potential help of the CRISPR system in finding targets for antimicrobials. In the context of combating multi-drug resistant strains, CRISPR provides hope for the diagnosis and treatment of infectious diseases.
Through the years, many promising tools for gene editing have been developed including zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), CRISPR-associated protein 9 (Cas9), and homing endonucleases (HEs). These novel technologies are now leading new scientific advancements and practical applications at an inimitable speed. While most work has been performed in eukaryotes, CRISPR systems also enable tools to understand and engineer bacteria. The increase in the number of multi-drug resistant strains highlights a necessity for more innovative approaches to the diagnosis and treatment of infections. CRISPR has given scientists a glimmer of hope in this area that can provide a novel tool to fight against antimicrobial resistance. This system can provide useful information about the functions of genes and aid us to find potential targets for antimicrobials. This paper discusses the emerging use of CRISPR-Cas systems in the fields of clinical microbiology and infectious diseases with a particular emphasis on future prospects.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据